CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & EFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT

The VEGF pathway remains an important target in GBM given its vascularity and autocrine VEGF signalling. Olinvacimab (TTAC-0001) is a fully humanised VEGFR2 Mab that binds and inhibits the receptor. This report assesses the safety, dosing schedules and efficacy of Olinvacimab in recurrent GBM. We co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Cher, Lawrence, Nowak, Anna, Iatropoulos, George, Bowyer, Samantha, Gan, Hui, Long, Anne Poh, Bynevelt, Michael, Jackson, Graeme, Lee, Seon Young, Lee, Weon Sup, Yoo, Jin-San
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650443/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.181
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados